Results 271 to 280 of about 275,929 (307)
Some of the next articles are maybe not open access.
Biotechnology and Bioprocess Engineering, 2002
Monoclonal antibodies (Mabs) have been used as diagnostic and analytical reagents since hybridoma technology was invented in 1975. In recent years, antibodies have become increasingly accepted as therapeutics for human diseases, particularly for cancer, viral infection and autoimmune disorders.
Hyo Jeong Hong, Sun Taek Kim
openaire +1 more source
Monoclonal antibodies (Mabs) have been used as diagnostic and analytical reagents since hybridoma technology was invented in 1975. In recent years, antibodies have become increasingly accepted as therapeutics for human diseases, particularly for cancer, viral infection and autoimmune disorders.
Hyo Jeong Hong, Sun Taek Kim
openaire +1 more source
Engineering monoclonal antibodies
Nature, 1989Efforts to alter the mAb component of pharmaceuticals have focused on making them more human-lIke and smaller. Ultimately, the smallest molecular recognition unit derived from antibodies may be a single complementarity region.
openaire +2 more sources
Engineering Antibodies for Biosensor Technologies
2005Publisher Summary The emphasis of this chapter is directed towards the progress made using genetically engineered antibodies that could provide solutions to many of the problems currently associated with the use of conventional antibodies in biosensor systems.
Sarah, Goodchild +3 more
openaire +3 more sources
Protein Engineering of Antibodies
Critical Reviews in Biotechnology, 1992This article reviews the technical advances in antibody engineering and the clinical applications of these molecules. Recombinant DNA technology facilitates the construction and expression of engineered antibodies. These novel molecules are designed to meet specific applications.
openaire +2 more sources
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Ca-A Cancer Journal for Clinicians, 2022Paolo Tarantino +2 more
exaly
Antibody variable region engineering for improving cancer immunotherapy
Cancer Communications, 2022Xuetao Cao
exaly
Avidity in antibody effector functions and biotherapeutic drug design
Nature Reviews Drug Discovery, 2022Simone C Oostindie +2 more
exaly